What to know about federal court ruling blocking mailing of widely used abortion pill

In the biggest jolt to abortion policy in the U.S. since the overturning of Roe v. Wade, a federal appeals court has restricted access to one of the most common ways to end early pregnancies, by blocking the mailing of mifepristone prescriptions. The unanimous ruling Friday from the New Orleans-based 5th U.S. Circuit Court of Appeals marks a substantial victory for abortion opponents seeking to stem the flow of abortion pills prescribed online that they view as subverting state bans on the procedure. READ MORE: Court restricts abortion access across U.S. by blocking the mailing of mifepristone The ruling, which is expected to be appealed to the U.S. Supreme Court, requires that mifepristone be distributed only in person and at clinics, overruling regulations set by the federal Food and Drug Administration. Here's what to know. Impact extends beyond states with abortion bans Frustrated with a lack of federal action against medicated abortions, Louisiana Attorney General Liz Murrill sued the FDA last month, saying its regulations undermined the state's ban on abortions at all stages of pregnancy. "The regulation creates an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law,"